4D Molecular Therapeutics Reports Positive 2-Year Phase 2b Results for 4D-150 in Wet AMD, Shows Reduced Treatment Burden and Strong Safety Profile 5678
4D Molecular Therapeutics Reports Positive 2-Year Data from ...
Sign in to continue:
4D Molecular Therapeutics Reports Positive 2-Year Data from ...
Netflix Q2 2026 Financial Report: Investor Highlights Ne...
Winning Catering Group, Inc. Q2 2026 Results: Shell Status, ...
Snow Rothschild Acquisition Corp. Q1 2026 Investor Update ...
GoodVision AI Announces Major 100 MW AI Factory Initiative i...
Organon & Co. 8-K Filing: Detailed Investor Analysis O...
Gogo Inc. Files Form 8-K: No Material Price-Sensitive Events...
Frontier Group Holdings, Inc. - Director Resignation Fro...
Trans American Aquaculture, Inc. Issues Non-Reliance Notice ...
Grayscale Avalanche Staking ETF: Material U.S. Federal Incom...